In this study we have examined the impact of common PIK3CA helical and catalytic domains hotspot mutations upon MET inhibition in preclinical MET-driven and head and neck cancer models, providing therefore a first evaluation of MET targeting in the context of common PI3K mutations. The gene discussed is PIK3CA; the disease is head and neck cancer.